Astrazeneca PlcAZN

NYSEHealthcarePharmaceutical Preparations
Price (close)
$166.58
Market cap
—
P/E
—
Revenue (FY)
$58.7B
Net income
$10.2B
Dividend yield
1.29%
1-year total return
14.5%
Net margin
17.4%
Revenue growth
8.6%
Debt / equity
0.51x

What Astrazeneca Plc does.

The information (including graphs and tabular data) set forth under the headings “Strategic Report—AstraZeneca at a Glance” on page 2, “Strategic Report—Chair’s Statement” on page 3, “Strategic Report—Chief Executive Officer’s Review” on pages 4 to 5, “Strategic Report—Financial highlights” on page 1, “Strategic Report—Healthcare in a Changing World” on pages 6 to 7, “Strategic Report—Our Purpose, Values and Business Model” on pages 8 to 9, “Strategic Report—Our Strategy and Key Performance Indicators” on pages 10 to 11, “Strategic Report—Therapy Area Review” on pages 12 to 25, “Strategic Report—Business Review” on pages 26 to 46, “Strategic Report—Risk Overview—Managing risk”, “—Emerging risks”, “—Climate risk”, “—Cybersecurity risk” on page 47, “Corporate Governance—Corporate Governance Report—Compliance with the UK Corporate Governance Code—Further information on risk management and controls—Global Compliance and GIA” on page 73, “Corporate Governance—Corporate Governance Report—Principal Decisions in 2025—Pipeline strengthening transactions” on page 77, “Financial Statements—Notes to the Group Financial Statements—Note 2—Revenue” on page 140 to 141, “Financial Statements—Notes to the Group Financial Statements—Note 7—Segment information” on pages 147 to 148, “Sustainability Statement” on pages 204 to 219, and “Additional Information—Important information for readers of this Annual Report—Statements of competitive position, growth rates and sales” on page 228, in each case of AstraZeneca’s “Annual Report and Form 20-F Information 2025” included as exhibit 15.1 to this Form 20-F dated February 24, 2026 is incorporated by reference.

Revenue and profit, by fiscal year.

Fiscal year202020212022202320242025
Revenue$26.6B$37.4B$44.4B$45.8B$54.1B$58.7B
Net income$3.2B$112.0M$3.3B$6.0B$7.0B$10.2B
Free cash flow$3.8B$4.9B$8.7B$9.0B$9.9B$11.8B

More on AZN.

Figures from Astrazeneca Plc's filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.